Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

S-Ethylisothiouronium diethylphosphate - TrioxBio

Drug Profile

S-Ethylisothiouronium diethylphosphate - TrioxBio

Alternative Names: Difetur; MTR 104; MTR-105; MTR-106; MTR-107; MTR-108; Nitric oxide synthase inhibitors - TrioxBio; Raviclust; Ravimig; Raviten

Latest Information Update: 06 Jun 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Meditor Pharmaceuticals
  • Developer TrioxBio
  • Class Antihypotensives; Antimigraines; Phosphates; Urea compounds
  • Mechanism of Action Nitric oxide synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Intradialytic hypotension
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Hypotension
  • Discontinued Intradialytic hypotension; Migraine

Most Recent Events

  • 29 May 2018 MTR 107 receives Fast Track designation for Intradialytic hypotension [IV, Injection] in USA
  • 29 May 2018 TrioxBio plans a phase II trial of MTR 107 for Intradialytic hypotension in USA in the fourth quarter of 2018
  • 31 Dec 2017 TrioxBio plans a phase II trial of MTR 106 for migraine in the US and Europe (TrioxBio Website, May 2018).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top